Citations

Clear

4207 citation(s) found for "Chen, Yu".

Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
Bazarbachi, Abdul-Hamid, Zanwar, Saurabh , Bodanapu, Geethika , Chen, Gui-Zhen , Kumar, Shaji , Lentzsch, Suzanne , Patwari, Anannya , Wang, Shikun , Cowan, Andrew J., Mellgard, George , Bazarbachi, Abdul Hamid , Hegenbart, Ute , Bhutani, Divaya , Chen, Guizhen, D’Souza, Anita , Dispenzieri, Angela , Gertz, Morie A. , Milani, Paolo , Muchtar, Eli , Palladini, Giovanni , Sanchorawala, Vaishali , Schönland, Stefan , Chakraborty, Rajshekhar

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 287-287

10.1182/blood-2024-202589 Get It

Background: Despite substantial improvements in early mortality (EM) for patients with systemic light chain amyloidosis (AL), rates remained high in the bortezomib-era, at approximately 25% (Muchtar et al. Blood. 2017). However, the therapeutic landscape in AL amyloidosis has changed with the ANDROMEDA trial, which led to the approval of daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (Dara-VCd) in the frontline setting. The incidence and predictors of EM in the context of daratumumab-based frontline therapy have not been studied. Methods: We performed an international multicenter retrospective cohort study of all consecutive patients with newly diagnosed AL treated with frontline Dara-VCd or Dara-Vd, and followed until 12/31/2023. EM was defined as death from any cause within 6 months of treatment initiation. Our primary objective was to identify the rate and significant predictors of EM. Univariate logistic regression was used to identify significant predictors of EM, which were then included in a multivariate logistic regression model. The receiver operator characteristic (ROC) analysis was used to determine the best threshold values that discriminated EM rates for the following continuous variables: age, dFLC (involved-uninvolved), eGFR, NT-proBNP, albumin, and high-sensitivity Troponin-T (hs-TnT). Other variables tested in univariate analysis were the following: ECOG performance status, NYHA functional class, sex, race, light chain isotype, percent bone marrow plasma cells, status of the following cytogenetic abnormalities-t(11;14), +1q, hyperdiploidy, del(13q), high-risk translocations, and del(17p), and the number of organs involved (2 vs 1). To build the clinical prediction score, each variable was weighted according to the β coefficient (natural logarithm of odds ratio) obtained from the multivariable regression. The β coefficients were rounded to the nearest 0.5 and multiplied by 2 to obtain an even number. Results The study cohort included 335 AL patients treated with daratumumab-based frontline therapy (92.2% Dara-VCd, 7.8% Dara-Vd), with all surviving patients having at least 6 months of follow-up. The median age at diagnosis was 66.5 years (range, 59.4 - 71.3), and 6.7% (n = 22) were Non-Hispanic blacks. Median dFLC at diagnosis was 22.91 mg/dL (range, 0.2-1093.4), and median NT-proBNP was 2415 pg/mL (range, 13-70,000). Mayo 2004 stages IIIA/IIIB represented 44% of the total cohort, with 17% having ECOG ≥ 2 and 25.4% having NYHA Class III/IV symptoms. The cumulative incidence of EM was 10.7%, with the incidence in patients with Mayo 2004 stage I, II, IIIA, and IIIB being 0%, 8%, 12.5%, and 25% respectively. On univariate analysis with unadjusted odds ratio (OR), the following variables significantly predicted EM: Age ≥ 75 (OR=2.8, p=0.013) ECOG ≥ 2, (OR 4.9, p<0.001), NYHA Class ≥ III (OR=4.95, p<0.001), dFLC ≥9 mg/dL (OR, 10.18, p=0.023), eGFR <33 mL/min/1.73 m2 (OR=2.7, p=0.026), NT-proBNP >5276 pg/mL (OR=7.69, p <0.001), hs-TnT >70 ng/L (OR=5.88, p<0.001), and absence of t(11; 14) (OR=2.33, p=0.041). These variables were entered into multivariate regression, except for ECOG and NYHA, which were combined to create a single variable (values ranging from 0-8), and hs-TnT was dropped due to substantial missing data as centers used different troponin assays. NT-proBNP was rounded to 5300 pg/ml for ease of clinical application. Based on the multivariate analysis, the following scores were assigned to each variable: Age ≥75 (2.0), ECOG+NYHA (1.0 x combined score), NT-proBNP >5,300 pg/ml (2.0), and absence of t(11;14) (3.0). This led to a score ranging from 1-15, and two risk-groups: low-risk (score <9; 87.5%) and high-risk (score ≥9; 12.5%). The respective cumulative incidence of EM was 6.1% versus 50% (p<0.001). The c-index of the model was 0.725 (95% CI, 0.676-0.774). Conclusion: Using variables that are readily available in the clinic, we have developed a two-tiered risk-prediction model for EM in AL amyloidosis in the context of daratumumab-based frontline therapy. The model needs to be externally validated in an independent dataset.
Disease Burden of Idiopathic and Lymphocytic Hypereosinophilic Syndrome in the United States: Evidence from a Real-World Retrospective Study of De-Identified Electronic Health Records and Insurance Claims
Dolin, Paul, Pongdee, Thanai , Rowell, Jennifer , Edmonds, Chris, Eudicone, James M. , Moore, Amanda , Peer, Thomas , Chen, S.Y., Jain, Priya Narayanan , Edmonds, Chris, Peer, Thomas, Chan, K. Arnold

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 2316-2316

10.1182/blood-2024-194822 Get It

Introduction: Hypereosinophilic syndrome (HES) is a group of rare diseases characterized by persistent hypereosinophilia in the blood and/or tissues, causing organ damage and dysfunction. This retrospective observational cohort study described the real-world disease burden and clinical characteristics of patients with idiopathic HES (I-HES) or lymphocytic HES (L-HES). Methods: Records of patients with I-HES or L-HES were collected from the TriNetX Linked Electronic Health Records (EHR) plus Claims Network, a database of de-identified EHR-derived data linked to closed claims data from healthcare organizations throughout the United States. Included patients had a first diagnostic record of HES (ICD-10-CM D72.11) between January 1st 2022 and September 12th 2023 and had continuous 12-month enrollment prior to their first HES diagnosis (index date), with gaps of up to 45 days permitted. Patients were excluded if they had myeloprolifertive or secondary reactive variant of HES, or an eosinophilic granulomatosis with polyangiitis diagnosis after their HES diagnosis. Baseline was defined as the 12-month period prior to the index date, and Year 1 was defined as the 12-month period after the index date. Analyses were descriptive. Results: At the index date, patients with I-HES or L-HES (N=53) had a mean (standard deviation [SD]) age of 41.6 (21.4) years, with nine (17.0%) patients aged less than 18 years, 15 (28.3%) of Black or African American race, and 27 (50.9%) of White race. The proportion of males was 60.4% (n=32). Prior to receiving an I-HES or L-HES diagnosis, 47.2% of patients either had an asthma diagnosis or were receiving inhaled corticosteroids or short-acting β2-agonist treatment but without a diagnosis of chronic obstructive pulmonary disease. Other common morbidities prior to I-HES/L-HES diagnosis were dorsalgia (28.3%), gastroesophageal reflux disease (20.8%), and hypertensive disease (20.8%). Amongst eosinophilic conditions, unspecified eosinophilia was recorded in 35.8% of patients and eczema was recorded in 18.9% of patients. In patients at baseline (N=53) and during Year 1 (n=19), the mean (SD) number of organ systems with HES signs and/or symptoms was 3.2 (2.3) and 2.7 (1.8), respectively. At baseline, 15.1% and 37.7% of patients had 3 or ≥4 organ systems, respectively, with I-HES or L-HES signs and/or symptoms; during Year 1, the proportion of patients with 3 or ≥4 organ systems with I-HES or L-HES signs and/or symptoms was 31.6% each. At baseline, I-HES and L-HES signs, symptoms and morbidities were most prevalent in the pulmonary system (60.4%), followed by the ears, nose and throat (41.5%), cardiovascular (35.8%), gastrointestinal (34.0%), cardiac (30.2%), and cutaneous (30.2%) systems. Compared with baseline, the proportion of patients during Year 1 with I-HES or L-HES signs, symptoms and morbidities was slightly higher for the pulmonary (63.2%) and cutaneous (36.8%) systems, and lower in the ears, nose and throat (36.8%), cardiovascular (31.6%), gastrointestinal (21.1%), and cardiac (26.3%) systems. Common I-HES and L-HES signs, symptoms and morbidities at the index date included: runny nose (34.0%), chest pain (32.1%), cough (32.1%), asthma (30.2%), dyspnea (28.3%), abdominal pain (24.5%), arthralgia (22.6%), eczema (18.9%), and heart palpitations (18.9%). Conclusion: I-HES and L-HES were associated with multiple morbidities and organ system involvement, indicating a high disease burden at the time of diagnosis. While I-HES and L-HES are primarily hematological disorders of hypereosinophilia, many other clinical specialties may diagnose and manage patients with these disorders.
Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
Gupta, Ashish O. , Sharma, Akshay , Frangoul, Haydar , Dalal, Jignesh , Alavi, Asif, Jaroscak, Jennifer, Ayala, Ernesto, Ziga, Edward, Rifkin-Zenenberg, Stacey , Chen, Guo , Chen, Yinzhong , Lin, Ling , Joseney-Antoine, Marcelyne, Ianniello, Leanne, Gardner, Beth, Hartigan, Adam J., Ciaramella, Giuseppe , Goyal, Sunita , Simon, Amy, Kanter, Julie , Alavi, Asif, DiPersio, John F. , Eapen, Mary , Minella, Alex C. , Chockalingam, Priya , Goyal, Sunita, Thompson, Alexis A. , Heeney, Matthew M.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 513-513

10.1182/blood-2024-204888 Get It

Fetal hemoglobin (HbF) is anti-sickling and elevated HbF ameliorates sickle cell disease (SCD) manifestations. BEAM-101 is an investigational cell therapy comprised of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that are base edited ex vivo to introduce naturally occurring A-to-G substitutions into the promoters of the HBG1/2 genes that encode γ-globin to disrupt BCL11A transcriptional repressor binding sites, leading to increased HbF production. We previously demonstrated in pre-clinical studies that base editing potently induced HbF (>60%) and proportionately reduced sickle hemoglobin (HbS) (<40%) without relying on double-stranded DNA breaks. We present initial data from BEACON (NCT05456880), a Phase 1/2, single-arm, open-label study evaluating the safety and efficacy of a single dose of BEAM-101 in patients with SCD with severe vaso-occlusive crises (VOCs). Patients 18-35 years diagnosed with SCD and ≥4 severe VOCs in the 2-year period prior to screening per trial criteria were eligible. After plerixafor mobilization, autologous CD34+ HSPCs were collected by leukapheresis/isolation and genetically modified with an adenine base editor. After myeloablative conditioning with pharmacokinetically adjusted busulfan, patients received a single infusion of BEAM-101 (≥3.0 × 106 viable CD34+ cells/kg) and are monitored for neutrophil and platelet engraftment, adverse events (AEs), total hemoglobin (Hb), Hb fractions, % F-cells, hemolysis markers, peripheral blood editing, and VOCs for 24 months. As of July 2, 2024, >20 patients are enrolled and BEAM-101 has been manufactured for 8 patients, of whom 6 patients have been dosed. One patient not included in this analysis discontinued during the mobilization/collection period prior to BEAM-101 treatment for non-medical reasons. Baseline demographics were as follows: 5/6 patients βS/βS, 1/6 patients βS/β0, all self-reported Black/African American, 50% female, aged 19-27 years. Of the 6 patients, half (n=3) required only a single mobilization cycle and the other half required 2. Patients received a mean BEAM-101 dose of 11.9 × 106 (5.2-23.4) viable CD34+ cells/kg. Excepting safety data that include all patients dosed (n=6), the following data are from patients dosed with ≥1 month of follow up (n=4; 6, 5, 2, and 1 month[s] post-treatment, each). All 4 patients with ≥1 month of follow up achieved neutrophil and platelet engraftment at a median of 17 (15-19) and 20 (11-34) days, respectively. One patient died due to respiratory failure, likely related to busulfan conditioning, 4 months after infusion. In all patients dosed (n=6), there have been no ≥Grade 3 AEs or serious AEs related to BEAM-101. Using the central laboratory data, patients' total Hb increased from baseline (mean 9.3 [7.9-10.9] g/dL) to 17.9, 18.2, 11.0, and 11.8 g/dL at last time point (LTP) available for P1, P2, P3, and P4, respectively. No signs/symptoms or interventions were undertaken for high total Hb. All patients achieved >60% HbF of non-transfused Hb (total Hb − HbA) at Month (M) 1 and sustained this elevation to the LTP available. By M1, HbS% in non-transfused blood dropped to ≤36% in all 4 patients and was sustained through LTP. In total blood, % F-cells were 99.6% in P1 at M6, 94.4% in P2 at M4, 52.0% in P3 at M2, and 13.3% in P4 at M1 with all patients having >19 pg HbF/F-cell at LTP available. Peripheral blood editing in nucleated cells, measured in P1 (at M6) and P2 (at M3), was 69.9% and 76.1%, respectively. Markers of hemolysis (lactate dehydrogenase, indirect bilirubin, haptoglobin, and reticulocyte counts) have normalized or improved for all patients. No VOCs have been reported by investigators following BEAM-101 treatment. These initial data show a safety profile for BEAM-101 consistent with busulfan conditioning and autologous HSCT. Treatment with BEAM-101 resulted in rapid engraftment, improvement in hemolysis markers, and marked improvement of anemia in all 4 dosed patients. We observed rapid and robust HbF induction consistent with pre-clinical data by M1 (>60%) and corresponding HbS reduction (≤36%) in non-transfused blood in all post-treatment assessments. No VOCs were reported by investigators post-treatment. These initial data support base editing of the HBG1/2 promoters as an effective therapeutic modality for the treatment of SCD and will continue to be investigated in the ongoing BEACON study. Updated data to be presented.
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study
Seymour, John F. , Allan, John N. , Advani, Ranjana H. , Eradat, Herbert, Lasica, Masa , By, Kunthel , Fabre, Shannon, Persky, Daniel O. , Advani, Ranjana H , Tam, Constantine S. , Cheah, Chan Y. , Parrondo, Ricardo D , Trotman, Judith , Zinzani, Pier Luigi , Treon, Steven P. , Chen, Xiangmei , Agarwal, Amit, Frustaci, Anna Maria

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 860-860

10.1182/blood-2024-199212 Get It

Introduction: Bruton tyrosine kinase (BTK) inhibitors are highly effective against Waldenström macroglobulinemia (WM). Their effectiveness can be limited by resistance caused by BTK mutations and intolerance. BGB-16673 is a bivalent small molecule that induces BTK degradation by binding specifically to BTK and the E3 ligase. The E3 ligase catalyzes the transfer of ubiquitin molecules to BTK, which marks BTK for destruction by the proteasome. Preclinically, BGB-16673 degraded wild-type and mutant BTK associated with covalentand noncovalent BTK inhibitors (ncBTKis), leading to tumor suppression. CaDAnCe-101 (BGB-16673-101; NCT05006716) is an ongoing, open-label, first-in-human, phase 1/2 study evaluating BGB-16673 monotherapy in patients with a range of B-cell malignancies. Here, early results in patients with WM enrolled in the phase 1 portion are presented. Methods: Eligiblepatients must have confirmed R/R WM (≥2 prior therapies), an ECOG performance status of 0-2, and adequate organ function. Patients must have previously received an anti-CD20 antibody and, in the US and EU, a covalent BTK inhibitor (cBTKi). BGB-16673 was orally dosed once daily in 28-day cycles. Dose escalation used a Bayesian optimal interval design (6 planned dose levels, 50-600 mg once daily). Primary objectives were to evaluate safety/tolerability (CTCAE v5.0) and to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Dose-limiting toxicities (DLTs) were assessed in the first 4 weeks (cycle 1). A secondary objective was to evaluate the overall response rate (ORR, IWWM-6 consensus criteria), with the first assessment occurring after 4 weeks of treatment. Results: As of May 24, 2024, 22 patients with WM were enrolled and treated (100 mg, n=4; 200 mg, n=10; 350 mg, n=8). The median age was 73.0 (range, 56-81) years, and the median number of prior therapies was 3.5 (range, 2-11), including prior cBTKis (n=22 [100%]), BCL2 inhibitors (n=4 [18%]), and ncBTKis (n=3 [14%]). Twenty patients (91%) had previously received chemotherapy. According to the International Prognostic Scoring System for WM, 6 patients (27%) had low-risk disease, 7 (32%) had intermediate-risk disease, and 8 (36%) had high-risk disease (missing/unknown data, n=1). Five patients (23%) had BTK mutations, 20 (91%) had MYD88 mutations, and 8 (36%) had CXCR4 mutations. The median follow-up was 4.3 (range, 0.3-21.3) months. Ninety-five percent of patients reported any-grade treatment-emergent adverse events (TEAEs; grade ≥3, 45%; serious, 23%), the most common (≥20%) of which were neutropenia/neutrophil count decreased (32%; grade ≥3, 23%), contusion (23%; no grade ≥3), and diarrhea (23%; no grade ≥3). The most common grade ≥3 TEAE (≥20%) was neutropenia/neutrophil count decreased. No atrial fibrillation, hypertension, febrile neutropenia, or major hemorrhage occurred. Three patients (14%) had a grade ≥3 infection (bronchopulmonary/cerebral aspergillosis, septic shock, and pseudomonal bacteremia/sinusitis). No patients had a TEAE that led to treatment discontinuation or dose reduction. No DLTs occurred, and the MTD was not reached. One patient (5%) died due to a TEAE (septic shock, considered related to disease progression). One patient died due to disease progression. In 21 response-evaluable patients (1 too early), the ORR (minor response or better) was 90%, the major response rate (partial response [PR] or better) was 81%, and the very good PR or better rate was 14%. Median time to first response was 0.95 (range, 0.9-3.7) months, with responses deepening over time. Seventeen patients remain on treatment and have ongoing responses. Responses were seen at the lowest dose (100 mg, 4/4), in patients previously treated with a cBTKi (19/21) and an ncBTKi (3/3), and in patients discontinued from prior BTKi due to disease progression (15/17). In addition, responses were observed in patients with and without mutations in BTK (with, 5/5; without, 6/8; unknown, 8/8), MYD88 (with, 18/20; without, 1/1), and CXCR4 (with, 8/8; without, 11/13). One patient had IgM flare at initial response assessment and went on to develop PR. Conclusions: Early data from this ongoing, first-in-human study demonstrate that the novel BTK degrader BGB-16673 has a tolerable safety profile and shows promising antitumor activity in heavily pretreated patients with BTK inhibitor-exposed R/R WM, including those with BTK and CXCR4 mutations.
Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial
Popat, Rakesh , Karlin, Lionel , Mazza, Irit Avivi, Kim, Seok Jin, Bar, Noffar , Horvath, Noemi , Spencer, Andrew , Min, Chang‐Ki, Li, Katherine , Slaughter, Ana, Lonardi, Carolina, Benachour, Nina, Vogel, Martin, Lendvai, Nikoletta , Lengil, Tamar, Patel, Nitin , Filho, Octavio Costa, Florendo, Erika, Lin, Yi, Popat, Rakesh , Oriol, Albert , Cavo, Michèle , Roeloffzen, Wilfried W. H. , Kim, Seok Jin , Lipe, Brea , Min, Chang‐Ki , Chen, Diana A. , Li, Quanlin , Ghosh, Arnab

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1032-1032

10.1182/blood-2024-201533 Get It

Introduction: Cilta-cel is approved in the US and EU for the treatment (tx) of patients (pts) with len-refractory MM after ≥1 line based on the randomized, phase 3 CARTITUDE-4 trial (NCT04181827). At the first interim analysis (15.9-month [mo] median follow-up), cilta-cel significantly improved progression-free survival (PFS) vs SoC (hazard ratio [HR], 0.26 [protocol-specified weighted analysis]; P<0.0001). At the second interim analysis, overall survival (OS) was significantly improved with cilta-cel vs SoC (HR, 0.55; P=0.0009). MRD negativity is a prognostic marker of prolonged survival outcomes for pts with MM. We report MRD negativity, including overall and sustained MRD negativity, overall MRD-negative complete response or better (≥CR), and MRD-negative ≥CR at mo 12, from the prespecified second interim analysis of CARTITUDE-4. Methods: Eligibility criteria were previously described. Pts were assigned 1:1 to cilta-cel or SoC (pomalidomide, bortezomib, and dexamethasone [PVd]/daratumumab, pomalidomide, and dexamethasone [DPd]). Pts in the cilta-cel arm underwent apheresis, received bridging therapy (PVd/DPd), and then a single cilta-cel infusion (target dose, 0.75×106 CAR+ viable T cells/kg) 5-7 days (d) after the start of lymphodepletion. PFS was the primary endpoint; ≥CR rate, overall response rate, overall MRD-negativity rate, and OS were key secondary endpoints. MRD was assessed centrally via next-generation sequencing (clonoSEQ v2.0; Adaptive Biotechnologies). MRD was evaluated at d 56 post infusion in the cilta-cel arm; and in both arms at suspected ≥CR and at 6, 12, 18, and 24 mo post infusion (cilta-cel arm) or cycle 1 d 1 (SoC arm), as well as yearly until progression/start of subsequent therapy in pts in ≥CR. Sustained MRD negativity (10−5) was defined as confirmed MRD negativity ≥12 mo apart and without MRD positivity in between. Pts were evaluable for sustained MRD negativity if they achieved MRD negativity and had ≥1 evaluable MRD sample ≥12 mo after the first negative result or progressed/died/started subsequent tx <12 mo after the first negative result. Results: 419 pts were randomized (intent-to-treat [ITT] set; cilta-cel, n=208; SoC, n=211); 176 pts in the cilta-cel arm received cilta-cel as study tx. As of May 1, 2024, median follow-up for the study was 33.6 mo. At the 10−5 threshold, 145 pts in the cilta-cel arm and 103 in the SoC arm were evaluable for MRD. MRD-negativity rates (10−5) in the ITT set and the MRD-evaluable subset were higher with cilta-cel vs SoC (ITT, 62% vs 18%; MRD evaluable, 89% vs 38%; both P<0.0001). Across subgroups, cilta-cel vs SoC consistently increased overall MRD-negativity rates (10−5). In the ITT set, 48% of the cilta-cel arm achieved MRD negativity (10−5) by d 56, with the MRD-negative rate rising to 60% by 6 mo post cilta-cel infusion. Overall MRD-negativity rates at the 10−6 threshold in the ITT set were higher with cilta-cel vs SoC (57% vs 9%; P<0.0001). In the cilta-cel arm, 119 (57%) pts vs 26 (12%) in the SoC arm achieved overall MRD-negative (10−5) ≥CR (P<0.0001). At the 12-mo MRD assessment, 92 (44%) pts in the cilta-cel arm vs 17 (8%) in the SoC arm (P<0.0001) had MRD-negative (10−5) ≥CR. In pts with MRD-negative (10−5) ≥CR at mo 12, median PFS was not reached (NR; 95% CI, not estimable [NE]-NE) with cilta-cel and 37.8 mo (95% CI, 25.0-NE) with SoC; median OS was NR (95% CI, NE-NE) and NR (95% CI, 37.8 mo-NE), respectively. Sustained MRD-negativity rates (10−5) in the ITT set were 40% in the cilta-cel arm vs 6% in the SoC arm (P<0.0001); among 110 and 26 evaluable pts for sustained MRD, sustained MRD-negativity rates were 75% vs 50% (P=0.0159). Among the 176 pts who received cilta-cel as study tx, overall MRD negativity at 10−5 was achieved by 129 (73%) pts (89% of 145 evaluable pts). Conclusions: At 33.6-mo median follow-up in CARTITUDE-4, cilta-cel vs SoC significantly increased overall MRD-negativity rates >3-fold in the ITT set, with pts achieving MRD negativity rapidly post cilta-cel. The prognostic value of MRD-negative ≥CR at mo 12 was shown, as median PFS was >3 years in pts with MRD-negative ≥CR at mo 12, regardless of tx. These data further underscore the benefit of cilta-cel, which led to significant >3-fold increases vs SoC in rates of MRD-negative ≥CR at any time and at mo 12, and sustained MRD negativity. Our MRD data demonstrate higher rates of deep and sustained MRD negativity achieved with cilta-cel vs SoC in tx of len-refractory MM as early as first relapse.
Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
Akahoshi, Yu , Inamoto, Yoshihiro , Spyrou, Nikolaos , Ayuk, Francis , Choe, Hannah , Doki, Noriko, Eto, Tetsuya, Etra, Aaron , Holler, Ernst , Vášová, Ingrid, Ishimaru, Fumihiko , Fukuda, Takahiro, Nakamura, Ryotaro , Atsuta, Yoshiko, Ferrara, James L.M. , Kanda, Yoshinobu , Akahoshi, Yu , Nakasone, Hideki , Doki, Noriko , Eto, Tetsuya , Hexner, Elizabeth O. , Hiramoto, Nobuhiro , Hogan, William J. , Kataoka, Keisuke , Tanaka, Masatsugu , Tanaka, Takashi , Uchida, Naoyuki , Chen, Yibin , Kanda, Junya , Atsuta, Yoshiko , Levine, John E. , Teshima, Takanori

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 384-384

10.1182/blood-2024-203344 Get It

Background Endpoints for GVHD treatment trials use early response (i.e, day (D)28 of treatment) as a surrogate for long term survival. Overall response (OR) that combines complete (CR) and partial responses (PR) at day (D) 28 is the conventional endpoint for primary acute GVHD trials because of similar survival outcomes between CR and PR. D28 OR ignores symptom severity at baseline and D28, however, and the PR category encompasses a wide range of responses from minimal improvement to near complete resolution of symptoms. D28 OR is the only endpoint currently approved by the FDA for efficacy, but it has not been re-evaluated as an endpoint for primary treatment (1L) in fifteen years and little is known regarding the prognostic value of D28 OR as an endpoint for second line treatment (2L) of GVHD. We hypothesized that refinement of the current D28 OR criteria, particularly through recategorization of PR in the GI tract, the main driver of nonrelapse mortality (NRM), would more accurately reflect disease control and better predict survival outcomes than current D28 response. Methods The Japanese Society for Transplantation and Cellular Therapy (JSTCT) collaborated with the Mount Sinai Acute GVHD International Consortium (MAGIC) to develop and validate D28 refined response (RR) criteria for 1L and 2L treatment (tx) in patients with Grades II-IV acute GVHD. To maximize the correlation between treatment success (i.e, response) with long term survival, our primary measured metric was the negative predictive value (NPV). We first randomly divided the 1L tx cohort of JSTCT into the training (n=2341) and validation sets (n=1156). In the training set we used a classification and regression tree (CART) algorithm to generate RR criteria that predicted 6-month (mo) NRM based on symptoms both at tx onset and D28. We then compared the two D28 response endpoints (RR vs OR) as surrogates for 6-mo NRM in two validation sets of both 1L tx (JSTCT: n=1156; MAGIC: n=1141) and 2L tx (JSTCT: n=510; MAGIC: n=196). Results The CART algorithm defined a RR as GVHD Grades 0/I at D28 without additional tx; all other D28 grades were considered refined nonresponses. As expected, RR successfully stratified the risk of 6-mo NRM in both 1L tx validation sets (JSTCT: 8% vs 38%, p<0.01; MAGIC: 9% vs 37%, p<0.01). We defined a discordant nonresponse as a nonresponse by RR criteria but a response by OR criteria, which accounted for the majority (~75%) of differences between RR and OR. 6-mo NRM in discordant nonresponders was four fold higher than in responders (JSTCT: 35%; MAGIC: 30%). The large majority (>80%) of discordant nonresponders had persistent GI GVHD at D28. Because the proportion of discordant nonresponders was small (<7% of the total population) in the 1L setting, the improvements of an already high NPV were small (JSTCT: 93% vs 91%; MAGIC: 91% vs 90%). In the 2L tx validation sets, RR also stratified the risk of 6-mo NRM (JSTCT: 26% vs 56%, p<0.01; MAGIC: 13% vs 55%, p<0.01). At the time of 2L tx, the discordant nonresponders are more common and half of the discordant nonresponders experienced 6-mo NRM (JSTCT: 45%; MAGIC: 59%); as a result, RR achieved much higher NPVs than OR (JSTCT: 75% vs 66%; MAGIC: 87% vs 76%). Deaths in responders from acute GVHD (vs. other causes such as infection) were more frequent in OR than RR in both 2L tx validation sets (JSTCT: 41% vs 20%; MAGIC: 41% vs 13%) and 1L tx validation sets (JSTCT: 25% vs 18%; MAGIC: 32% vs 29%). D28 RR is superior to OR because it more accurately reflects control of serious GVHD in four independent validation cohorts, particularly in patients with GI disease. Conclusion We conclude that RR is a more accurate endpoint than OR in patients with grade II-IV GVHD primarily because it classifies persistent GI GVHD at D28 as a non-response instead of a response, which correlates with 6-mo NRM and achieves a higher NPV. This validated RR metric can serve as a better endpoint than OR in assessing treatment efficacy in both primary treatment trials that enrich for high risk GVHD, e.g. GI involvement, and second line treatment trials.
Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
Pabmanabhan, Anand, Splinter, Noah P., Mauch, Emily, Kanack, Adam J. , Pruthi, Rajiv K. , Kumar, Shaji, Pabmanabhan, Anand, Chen, Dong , Dispenzieri, Angela , Kumar, Shaji , Houghton, Damon E.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 3996-3996

10.1182/blood-2024-207999 Get It

Introduction. Platelet-activating anti-Platelet factor 4 (PF4) antibodies mediate a number of thrombotic thrombocytopenic syndromes, including heparin-induced thrombocytopenia (HIT), and more recently recognized conditions, vaccine-induced immune thrombotic thrombocytopenia (VITT), adenovirus-associated thrombotic thrombocytopenia, and monoclonal gammopathy of thrombotic significance (MGTS). In MGTS (Blood. 2023 Apr 6;141(14):1772-1776), a monoclonal IgG antibody to PF4 mediates a chronic prothrombotic state characterized by recurrent thrombosis. More recent evidence suggests that MGTS may present with negative results in HIT enzyme-linked immunosorbent assay (ELISA) and serotonin release assay (SRA), and positivity only in PF4-dependent functional assays such as the PF4-dependent P-selectin expression assay (PEA; submitted). The presence of MGUS in patients has long been associated with high risks of thrombotic disease (Blood. 2010 Jun 17;115(24):4991-8), but the mechanism by which they predispose to thrombosis has been relatively unexplored. In this study, we evaluated a cohort of MGUS patients who experience thrombosis for the presence of platelet-activating anti-PF4 antibodies. M ethods. An administrative database search was performed of Mayo Clinic records to identify patients who had a diagnosis of MGUS, and thrombosis. Research samples from 134 MGUS patients with IgG monoclonal protein and thrombosis were obtained from Mayo Clinic's dysproteinemia biobank and subjected to PF4 antigen-based and functional screening. Research studies were approved by the Institutional Review Board of Mayo Clinic. Results. Of the 134 patients, 17 (12.7%) activated platelets in the PEA (≥19%). To exclude non-specific activation (e.g. due to HLA antibodies), secondary PEA testing was performed to assess whether platelet activation was mediated by a HIT-like antibody (i.e., PF4- and IgG-dependent, and inhibitable with high concentrations of heparin). Four patients, hereafter referred to as patients 1-4, were identified as having a HIT-like antibody, as demonstrated by PF4-dependent platelet activation that could be inhibited with high concentrations of heparin (100 U/mL), and blockade of the platelet IgG receptor, FcγRIIa. Patients 1 and 2 had persistent, platelet-activating anti-PF4 antibodies based on PEA testing of multiple samples obtained several years apart. Patient 1 had a recurrent, multi-year history of deep venous thrombosis (DVT), while patient 2 had one DVT episode. Patient 3 demonstrated a HIT antibody-like profile in the PEA in two of three samples available for testing and had a history of thrombotic cerebrovascular accident (CVA). Patient 4 demonstrated a HIT-like platelet-activating antibody in only one of four samples tested, and consistent with this finding, had an MGUS identified on clinical testing at only one time point (“small” IgG lambda, not quantified), 3 months prior to the platelet-activating sample. This patient experienced multiple thrombotic events including DVTs, left atrial thrombus and embolic CVA, pulmonary embolism and acute limb ischemia. All patients tested negative in two FDA-approved antigen-based HIT assays tested (Immucor PF4 IgG and Zymutest HIA IgG), similar to a recent MGTS case (submitted). SRA was negative in both Patients 1 & 2, weakly positive in Patient 3 (33%, with high CV), and positive (72%) in Patient 4. Conclusions. Definitive diagnosis of patients with MGTS provides insight into a mechanism of “unexplained” thrombosis and may offer additional treatment pathways for these patients with recurrent thrombosis (New Eng J of Med, 2024 Aug 8). Serologic testing in two patients correlated strongly with observations of thrombosis, and the study confirmed recent findings that anti-PF4 antibodies may present with unusual serology that is neither HIT- nor VITT-like (with negative results in both ELISA and SRA). The incidence of confirmed/suspected MGTS was 3% (4/134) in this population of MGUS patients with thrombosis. Prospective studies are needed to confirm these observations.
Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Pri
Chanan‐Khan, Asher , Mudenda, Boyd, Nogaieva, Larysa, Kryachok, Iryna, Usenko, Ganna, Ivanov, Vladimir , Perekhrestenko, Tetiana , Muzhychuk, Ivan, Myasnikov, Alexander G., Lukavetsky, L.M., Proydakov, Andrei, Uspenskaya, Olga, Borisenkova, Elena , Marlton, Paula , Winter, Allison , Lysa, Tamila, Ahmad, Mohammad, Liang, Zhiyan , Mekala, Divya J. , Karpenko, Olena, Osipov, Iurii , De, Asit K. , Wang, Hengbang , Gabrail, Nashat , Ganju, Vinod , Константинова, Т. С. , Samoilova, Olga, Yang, Dajun, Davids, Matthew S. , Ailawadhi, Sikander , Kyselova, Olena , Myasnikov, Alexander, Uspenskaya, Olga, Siddiqi, Tanya , Бакиров, Б. А. , Fu, Tommy , Li, Mingyu , Chen, Zi , De, Asit, Samoilova, Olga , Yang, Dajun , Zhai, Yifan

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4614-4614

10.1182/blood-2024-207408 Get It

Introduction BCL-2 inhibition with venetoclax (ven) was a major advance in CLL treatment, but the 5-week dose ramp-up to mitigate the risk of tumor lysis syndrome and drug-drug interactions (DDIs) challenge treatment optimization. Lisaftoclax is an investigational, oral BCL-2i with a short half-life, allowing it to be ramped-up on a daily schedule. We present updated results of a phase 1b/2 study of lisaftoclax alone or combined with acalabrutinib or rituximab in pts with treatment-naïve (TN; lisaftoclax-acalabrutinib arm), relapsed/refractory, or prior ven-treated CLL/SLL (NCT04215809). Methods Pts were treated with a rapid 4- to 6-day daily ramp-up of lisaftoclax from 20 mg to a target dose of 400, 600, or 800 mg, receiving daily oral lisaftoclax alone or, plus continuous acalabrutinib or 6 cycles of rituximab in 28-day cycles, starting on Cycle 1 Day 8 (C1D8) until disease progression, complete response by C24, or unacceptable toxicity. Intensive blood samples were collected for pharmacokinetic (PK) and exposure-response (E-R) analyses. Results From March 20, 2020, to June 27, 2024, 176 pts were enrolled: 46 in monotherapy and 39 and 91 in rituximab and acalabrutinib combination cohorts, respectively; 154/176 (87.5%) were R/R and 22/176 (12.5%) TN. The median (range) age was 63 (34-80) years; 67% were male; 25.6% had del(17p) and/or TP53 mutation; and 70.6% had unmutated IGHV. Median (range) duration of treatment with lisaftoclax was 16.5 (1-54; monotherapy), 24 (3-39; rituximab), and 27 (1-43; acalabrutinib) months. In R/R pts, the median (range) number of prior lines of therapy was 2 (1-15), and 14 (9%) pts had been treated with ven. Prior ven pts had a median (range) age of 65 (51-78); 79% were male; of evaluable pts, 50% had del(17p), 36% TP53 mut, 64% del(11q), 38% complex karyotype (≥ 3 abnormalities), and 92% unmutated IGHV; 57% were BTKi naïve; and the median (range) number of prior therapies was 3 (1-6). Incidence and severity of TEAEs were similar across cohorts. Common (>10%) any-grade TEAEs in all cohorts combined were neutropenia (59 [33.5%]), diarrhea (38 [21.6%]), anemia (27 [15.3%]), and thrombocytopenia (26 [14.8%]). Grade ≥ 3 TEAEs were neutropenia in 15 (32.6%), 10 (25.6%), and 22 (24%) pts and anemia in 10 (21.7%), 5 (12.8%), and 12 (13.2%) pts in monotherapy, rituximab, and acalabrutinib combination cohorts, respectively. Comprehensive E-R analyses indicated that lisaftoclax had similar systemic exposure as monotherapy or when combined with acalabrutinib or rituximab; lisaftoclax had no DDI when combined with acalabrutinib or rituximab. No discontinuations were attributed to lisaftoclax TRAEs. Forty-four (95.7%) pts in monotherapy discontinued treatment. Most discontinuations were due to progressive disease (n = 41 [23.3%]) and 13 (7.4%), AEs; 9 (5.1%) pts withdrew consent; 7 (4%) achieved complete response or MRD negativity after ≥ 24 cycles; 5 (2.8%) died; and 18 (10.2%) discontinued for other reasons. Clinical (n = 2) and laboratory (n = 3) TLS was observed in 5 (2.8%) pts on lisaftoclax (by Howard/Cairo-Bishop criteria), with cases rapidly resolving to resume lisaftoclax safely. ORR for lisaftoclax plus acalabrutinib in 87 pts was 96.6%, and the median DOR (95% CI, 23-NR) and median PFS (95% CI, 34-NR) were not reached. The 12- and 18-month PFS rates were 89% and 86%, respectively. Fourteen R/R CLL ven-exposed pts received lisaftoclax plus acalabrutinib, of whom 9 had progressed on ven, 3 relapsed after completing ven, and 2 discontinued due to ven intolerance. Median (range) duration of treatment was 16 (3-25) months. Safety profile was similar to that of other study cohorts. ORR was 85.7% (12/14), 100% (8/8), and 66.7% (4/6) in the ven-exposed, ven-exposed but BTKi-naïve, and ven- and BTKi-exposed pts, respectively. The median duration of response (DOR) and progression-free survival (PFS) were not reached. The 12- and 18-month PFS rates were 84% and 73%, respectively. Conclusions Our data suggest that lisaftoclax combined with acalabrutinib is effective for pts with prior ven exposure, including those with progression on ven. In this updated analysis with longer follow-up, no DDIs or new safety findings were observed in TN or R/R CLL/SLL pts treated with lisaftoclax monotherapy/combinations. We continue to accrue pts with prior ven exposure to further evaluate this promising signal. A global registrational phase 3 study GLORA (NCT06104566) is recruiting.
Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
Borate, Uma , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Blum, William , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja, Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Byrd, John C. , Byrd, John C. , Byrd, John C , Welkie, Rina Li , Traer, Elie , Lin, Tara L. , Madanat, Yazan F. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Chen, Timothy Frank , Druker, Brian J , Levine, Ross L. , Mims, Alice S

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1564-1564

10.1182/blood-2024-211261 Get It

Background: Chromosomal rearrangements involving the KMT2A gene and mutations involving the nucleophosmin (NPM1) gene have been associated with response to menin inhibitors in multiple studies of acute myeloid leukemia (AML) patients characterized by these genetic alterations. Both alterations are more common in younger AML patients and those with NPM1 mutations historically perform better. However, the prevalence and outcomes of older (≥60 years) AML patients with these alterations who are treated with current therapies is less well understood. We present results from the Beat AML Master Trial (BAMT) that analyze the outcomes of this large, but less common subset of patients in an older AML population. Methods: Patients were consented and enrolled on this precision medicine-based Beat AML Master Trial (NCT03013998) from November 2016 to June 2024. Patients were included in this analysis if they harbor either the classic NPM1 mutation or a KMT2A rearrangement (over 10 different gene partners). Additionally, 2 patients with a NUP98 rearrangement were included with the KMT2A cohort as they are known to have similar biology in terms of menin dependence. These patients were treated with the following therapies: a sub-study specific targeted therapy for the dominant clone, venetoclax + hypomethylating agent (Ven/HMA), intensive chemotherapy (IC), alternative non-intensive therapy (NIT), or no therapy. Clinical/genetic characteristics and median overall survival (OS) were analyzed in each group separately. Overall survival (OS) was calculated from master consent and estimated using the Kaplan-Meier method. Results: Of 1096 AML patients enrolled on the BAMT, 246 patients had either an NPM1 (N=207, 18.9%) or KMT2A (N=39, 3.6%) genetic alteration. The baseline characteristics for the NPM1 cohort were median age 72 years (range: 60-92), 50% female, and ECOG performance status: 0-16%, 1-58%, 2-25% and 3-1%. Additional disease characteristics include treatment related AML at 11% and complex karyotype (≥3 abnormalities) at 3%. Median OS for the entire NPM1 cohort was 18.4 months (95% CI: 14.2-24.7). Patients were treated on a sub-study (35%), Ven/HMA (19%), IC (26%), NIT (8%) or no treatment (9%). Between treatment groups, median OS was 21 months (95% CI: 12.8-31.7) for those treated on a sub-study, 22 months (95% CI: 12.6-not reached (NR)) for Ven/HMA, 41.6 months (95% CI: 18.2-NR) for IC, and 6.3 months (95% CI: 1.3-23) for NIT, which was significantly different (p<0.0001). The baseline characteristics for the KMT2A cohort were median age 69 years (range: 60-88), 44% female, and ECOG performance status: 0-19%, 1-45%, 2-35% and 3-0%. Treatment related AML occurred in 23% of patients and complex karyotype in 31%. Median OS for the KMT2A cohort was 6.5 months (95% CI: 3.6-31.6). Patients were treated on a sub-study (38%), Ven/HMA (15%), IC (15%), NIT (15%), or no treatment (5%). Between treatment groups, median OS was 31.6 months (95% CI: 3.2-NR) for sub-study, 5.0 months (95% CI: 3.0-NR) for Ven/HMA, 12.7 months (95% CI: 4.9-NR) for IC, and 2.9 months (95% CI: 1.5-NR) for NIT, which was also significantly different (p<0.0001). Conclusions: In this cohort of older AML patients who possess NPM1 or KMT2A mutations, initial demographics and clinical characteristics upon presentation are as expected. Within each cohort and depending on the type of therapy received, there were interesting differences in survival. Median OS was the highest for the NPM1 cohort that received IC while the KMT2A cohort had the highest median OS when enrolled on a KMT2A targeted sub-study; a finding that supports precision-based medicine for this high-risk KMT2A group characterized by poor outcomes. As menin inhibitor combinations with induction chemotherapy or Ven/HMA move to the frontline setting, we anticipate seeing significant improvement in outcomes for AML patients in both of these genomic subsets. Further multivariable analysis will be performed to validate treatment effect on OS. Our analyses for these two cohorts also provide valuable outcome benchmarks for the design of future precision oncology studies that seek to improve survival in these subsets of older AML patients.
Matching-Adjusted Indirect Comparisons (MAICs) of Odronextamab Versus Mosunetuzumab and Epcoritamab for the Treatment of Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) after Two or More Lines of Systemic Therapy
Jagadeesh, Deepa , Novelli, Silvana , Xu, Yadan , Kamat, Siddhesh , Mastikhina, Liza , Ambati, Srikanth, Chan, Keith, Cope, Shannon , Keeping, Sam , Caisip, Clyde, Chaudhry, Aafia, Harnett, James , Luminari, Stefano , Taszner, Michał , Merli, Michele , Chen, Jenny , Mohamed, Hesham , Villasboas, José C.

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 7803-7803

10.1182/blood-2024-200865 Get It

Introduction In ELM-2 (NCT03888105), a Phase 2, open-label, multicohort study, odronextamab monotherapy demonstrated encouraging clinical efficacy, generally manageable safety, and maintenance of patient-reported outcomes in R/R FL (Chong et al. AACR 2024; Tessoulin et al. ASH 2023). In the absence of head-to-head clinical trials comparing CD20×CD3 bispecific antibodies in R/R FL, two unanchored MAICs were conducted to evaluate the efficacy of odronextamab versus mosunetuzumab and epcoritamab in patients with R/R FL in the third-line or later (3L+) setting. Methods Patient-level data from the ELM-2 R/R FL cohort receiving odronextamab (N=128; data cutoff: October 2023) were compared with published data from similar cohorts in the GO29781 trial of mosunetuzumab (N=90; Budde et al. Lancet Oncol 2022) and EPCORE NHL-1 trial of epcoritamab (N=128; Linton et al. Lancet Haematol 2024). To adjust for baseline differences in the trial populations, a priori-identified prognostic variables (progression of disease within 2 years, primary refractory, refractory to last line of therapy [LOT], number of prior LOTs, serum lactate dehydrogenase level, Eastern Cooperative Oncology Group performance status, Follicular Lymphoma International Prognostic Index, age at start of LOT, and Ann Arbor disease stage) were included in the base-case MAICs. Two additional variables (double refractory and prior autologous stem cell transplant), reported in ELM-2 and the comparator studies, were included in a sensitivity analysis. The MAICs reported here were focused on response outcomes as assessed by independent central review, which were reported across trials. Relative treatment effects before and after matching were presented as odds ratios (ORs), along with 95% confidence intervals (CIs). Results The effective sample size for odronextamab was 102.0 after matching with mosunetuzumab and 90.6 after matching with epcoritamab in the base-case MAICs. All key prognostic variables were balanced between ELM-2 and both comparator trials in each analysis. Before and after matching, odronextamab demonstrated comparable objective response rates (ORRs) and significantly higher complete response (CR) rates versus mosunetuzumab (before matching: ORR 80.5% vs 80.0%, OR 1.03 [95% CI 0.52-2.03], p=0.93; CR rate 73.4% vs 60.0%, OR 1.84 [95% CI 1.04-3.28], p=0.04; after matching: ORR 83.5% vs 80.0%, OR 1.27 [95% CI 0.61-2.65], p=0.53; CR rate 75.7% vs 60.0%, OR 2.08 [95% CI 1.12-3.86], p=0.02). Odronextamab demonstrated numerically higher CR rates versus epcoritamab before and after matching (before matching: CR rate 73.4% vs 62.5%, OR 1.66 [95% CI 0.98-2.82], p=0.06; after matching: CR rate 69.4% vs 62.5%, OR 1.36 [95% CI 0.77-2.41], p=0.29). The ORRs of odronextamab and epcoritamab were comparable before matching (ORR 80.5% vs 82.0%, OR 0.90 [95% CI 0.48-1.69], p=0.75) and after matching (ORR 78.1% vs 82.0%, OR 0.78 [95% CI 0.40-1.53], p=0.47). Consistent results were observed in the sensitivity analyses. Conclusions In the absence of head-to-head clinical trials comparing bispecific antibodies in the setting of 3L+ FL, MAICs demonstrate that odronextamab was associated with higher CR rates compared with mosunetuzumab and epcoritamab. Since achieving a CR in the R/R FL setting is an important treatment goal, our results highlight the potential of odronextamab as an effective treatment option in R/R FL.